CSL Behring Celebrates World Hemophilia Day
Global Drug Manufacturer CSL Behring announced last week it’s recognition of World Hemophilia Day by sharing news of a donation of more than 4 million international units (IUs) of its medicines to treat hemophilia A and/or von Willebrand Disease to the WFH Global Alliance for Progress (GAP) Program.To read the full release from CSL Behring, click […]
Genentech Announces Interim Results from Phase III HAVEN 2 Study
On April 16, 2017 Genentech announced interim results from the Phase III HAVEN 2 study evaluating emicizumab prophylaxis in children less than 12 years of age with hemophilia A and inhibitors to factor VIII. According to this Genentech’s press releases, “interim analysis after a median of 12 weeks of treatment, emicizumab prophylaxis showed a clinically meaningful reduction in the […]
Pharmaceutical Companies Recognize World Hemophilia Day
Today, on World Hemophilia Day, many pharmaceutical companies joined in the celebration by recognizing and supporting the hemophilia community. Linked below are statements from a wide group of companies on today’s celebration of World Hemophilia Day:Grifols Press ReleaseBioverativ Press ReleaseNovo Nordisk on supporting women with bleeding disordersShire Press ReleaseCSL Behring Press Release
Novo Nordisk Recognizes World Hemophilia Day
Drug manufacturer, Novo Nordisk recognized World Hemophilia Day 2017 by celebrating the theme of the year; Hear Their Voices, by showing support for women with bleeding disorders. To learn more, read Novo Nordisk’s press release in it’s entirety. here.
Shire Recognizes World Hemophilia Day
Clotting factor manufacturer, Shire, is celebrating World Hemophilia Day in part by hosting an awareness rally in Chicago, Illinois. The rally is aimed mainly to educate the public on the dramatic estimate of a hemophilia bleeding episode occurring worldwide every 3-15 seconds. See more on their website.Read a full statement from Shire recognizing World Hemophilia Day.
Grifols Donates 140 Million Units of Factor on World Hemophilia Day
As part of World Hemophilia Day celebrations, Grifols has announced a large donation of clotting factor to the World Federation of Hemophilia (WFH) Humanitarian Aid Program. This announcement is a continuation of the company’s three-year commitment from 2014, bringing the total humanitarian aid commitment to more than 200M IU of Factor VIII over eight yearsRead the full […]
Catalyst Biosciences Completes New Hemophilia B Drug Toxicology Study
On April 11, Catalyst Biosciences, a clinical-stage biopharmaceutical company focused on developing novel medicines to address hematology indications, reached a key milestone towards starting human trials with completion of the CB 2679d/ISU304 toxicology studies. Their press release can be read in full here.
Aptevo's Ixinity Found To Be Safe In Children Under 12 With Hemophilia B
Aptevo’s Ixinity, previously approved for use in people over the age of 12, just received approval for use in children under 12, per their ongoing phase 3 trial. Read the full press release here.
Spark Therapeutics Presents Updated Preliminary Data from Hemophilia B Phase 1/2 Trial
Spark Therapeutics issued a press release on updated preliminary data from 10 infused participants in the ongoing Phase 1/2 clinical trial of investigational SPK-9001 for hemophilia B. The data is being presented at Hemostastis & Thrombosis Research Society (HTRS) this week.The press release can be read in full here.
Spark Therapeutics Announces Phase 1/2 Gene Therapy Trial for Hemophilia A
Note: The following is an edited version of a press release from Spark Therapeutics. Read the press release from Spark Therapeutics in it’s entirety here. Spark Therapeutics has announced that its Phase 1/2 trial for the investigation of gene therapy for hemophilia A (factor VIII deficiency) has begun. This trial will initially be enrolling participants at the Children’s Hospital […]
English 
Español de Puerto Rico